Skip to main content

Avalo Therapeutics, Inc.

AVTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001534120

In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 16, 2026
$426.2M
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $1.87M in total
5
13F holdersQ2 2026, +29 vs. previous quarter
126
13F valueReported value at the end of Q2 2026
$1.31B
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$59.0K
−86.6% year over year
Net income, FY2025
-$78.3M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $78.3M (132642.4% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
8.91M
Shares sold short
Change
−3.05M
−25.5% vs. previous
Days to cover
2.09
At average daily volume

Superinvestors holding AVTX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding AVTX at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Avalo Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 18, 2026 (view filing)4:10 PM ETSep 162 daysSullivan Christopher RyanChief Financial OfficerSSale−12.4K$16.33−$202.4K−23.7%39.9K after10b5-1
Sep 11, 2026 (view filing)4:10 PM ETSep 101 daySullivan Christopher RyanChief Financial OfficerSSale−10.2K$17.62−$179.5K−20.3%39.9K after10b5-1
Sep 1, 2026 (view filing)4:38 PM ETAug 284 daysDoyle MittieChief Medical OfficerSSale−679$20.00−$13.6K−1.3%51.8K after10b5-1
Aug 19, 2026 (view filing)4:10 PM ETAug 17-182 daysSullivan Christopher RyanChief Financial OfficerSSale−72.7K$19.94−$1.45M−64.6%39.9K after3 lots10b5-1
Aug 19, 2026 (view filing)4:10 PM ETAug 172 daysDoyle MittieChief Medical OfficerSSale−1.00K$20.00−$20.0K−1.9%51.8K after10b5-1
Aug 12, 2026 (view filing)4:10 PM ETAug 111 dayRiley JenniferChief Strategy OfficerSSale−2.65K$19.59−$52.0K−6.7%37.0K after
Aug 12, 2026 (view filing)4:10 PM ETAug 102 daysDoyle MittieChief Medical OfficerSSale−679$20.00−$13.6K−1.3%51.8K after10b5-1
Jul 29, 2026 (view filing)4:05 PM ETJul 272 daysDoyle MittieChief Medical OfficerSSale−1.00K$20.00−$20.0K−1.9%51.8K after10b5-1
Jul 2, 2026 (view filing)4:05 PM ETJun 302 daysDoyle MittieChief Medical OfficerSSale−4.65K$20.00−$93.1K−8.2%51.8K after10b5-1
Jun 25, 2026 (view filing)Jun 232 daysDoyle MittieChief Medical OfficerSSale−1.45K$18.00−$26.1K−2.7%51.8K after10b5-1

Top 10 13F holders, Q2 2026

See all 126 holders

The largest institutional positions in Avalo Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding AVTX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC5,100,216$94.3M0.00%+2,220,735+77.1%Added
BlackRock, Inc.4,365,553$80.7M0.00%+4,038,471+1,234.7%Added
Deep Track Capital, LP3,610,000$66.7M0.98%+3,610,000New
Caligan Partners LP3,163,866$58.5M2.82%+1,528,843+93.5%Added
TCG Crossover Management, LLC3,017,120$55.8M1.34%+2,278,737+308.6%Added
Affinity Asset Advisors, LLC2,900,000$53.6M2.62%+1,559,160+116.3%Added
State Street Corp2,889,287$53.4M0.00%+2,817,633+3,932.3%Added
Farallon Capital Management, L.L.C.2,498,000$46.2M0.27%+1,582,000+172.7%Added
Point72 Asset Management, L.P.2,387,026$44.1M0.07%+1,470,884+160.6%Added
Avoro Capital Advisors LLC2,333,333$43.1M0.39%+923,333+65.5%Added

Holders of 5% or more of AVTX

See all 11 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Avalo Therapeutics, Inc..

Largest holders of AVTX from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Commodore Capital LP13G9.90%5.72M sharesNewJun 18, 20261 filingJun 18, 2026SEC
TCG Crossover GP II, LLC13G7.90%3.02M sharesNewMay 12, 20261 filingMay 12, 2026SEC
Farallon Capital Management, L.L.C.13G7.40%3.97M sharesNewNov 13, 20261 filingNov 13, 2026SEC
Deep Track Capital, LP13G/A6.87%3.61M shares+1.06 ppfrom 5.81%Apr 5, 20244 filingsAug 14, 2026SEC
BlackRock, Inc.13G6.50%3.42M sharesNewJul 27, 20261 filingJul 27, 2026SEC